AdaptHealth Corp. (AHCO) Stock Price & Analysis
AdaptHealth Corp. (AHCO) closed at USD 6.03 on Wednesday, October 28, 2026, up 3.08% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.03; the Oct 28, 2026 session ranged USD 5.82–6.08 on volume of 1,558,583 shares. Market capitalization is —, with a 52-week range of USD 5.21–13.43 (NCM). Source: Nexqual, retrieved October 29, 2026 at 06:17 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AHCO.md
Key facts (AHCO)
- Last four reported quarters (through Jun 30, 2026): revenue $3.23B, net income -$228M (-7.1% margin), free cash flow $97.7M (SEC filings).
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $231K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $395K; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -34.2% vs S&P 500 +13.6%; 5Y -77.9% vs S&P 500 +79.8%.
- Next earnings: 2026-11-03, EPS estimate USD -0.06, revenue estimate $726M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AHCO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.45B | $2.97B | $3.20B | $3.26B | $3.24B | $3.23B |
| Gross profit | $446M | $580M | $624M | $681M | $609M | — |
| Operating income | $226M | $190M | -$598M | $264M | $90.9M | -$144M |
| Net income | $156M | $69.3M | -$679M | $90.4M | -$70.8M | -$228M |
| EPS (diluted) | $0.67 | $0.33 | -$5.31 | $0.61 | -$0.52 | — |
| Free cash flow | $72.4M | -$17.6M | $143M | $236M | $219M | $97.7M |
| Gross margin | 18.2% | 19.5% | 19.5% | 20.9% | 18.8% | — |
| Operating margin | 9.2% | 6.4% | -18.7% | 8.1% | 2.8% | -4.5% |
| Net margin | 6.4% | 2.3% | -21.2% | 2.8% | -2.2% | -7.1% |
| Revenue growth | +132.4% | +21.0% | +7.7% | +1.9% | -0.5% | — |
| Cash + short-term investments | $150M | $46.3M | $77.1M | $110M | $106M | — |
| Total debt | $2.20B | $2.19B | $2.15B | $1.98B | $1.74B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (AHCO)
P/E at fiscal year-ends: Dec 2024 14.3x.
Insider sales (SEC Form 4, open-market, last ~7 months) (AHCO)
2 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Schuster Iii Russell E. | Chief Commercial Officer | 11,275 | $118K | 8.3% | Yes (adopted March 2, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-01 | Schuster Iii Russell E. | Chief Commercial Officer | 11,275 | $113K | 7.6% | Yes (adopted March 2, 2026) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (AHCO)
2 purchases, $395K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-06…2026-08-07 | Wolf Dale B | Director | 40,000 | $245K | 6.12 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-08-06 | Samet Kenneth A | Director | 23,500 | $150K | 6.38 | Too little history (no open-market trades in 2023–2025) |
Analysts (AHCO)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-17 | Baird | Target lowered | Outperform | $10 → $9 |
| 2026-08-06 | UBS | Target lowered | Buy | $14 → $10 |
| 2026-08-06 | RBC Capital | Target lowered | Outperform | $15 → $8 |
| 2026-08-05 | Truist Securities | Target lowered | Buy | $14 → $9 |
| 2026-07-21 | Jefferies | Upgrade | Hold → Buy | $11 → $13 |
| 2026-07-06 | Baird | Target lowered | Outperform | $18 → $15 |
Total return (dividends reinvested) (AHCO)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -34.2% | -77.9% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -34.3% | -26.0% |
| Volatility (annualized) | 68.9% | 61.4% |
| Max drawdown | -61.0% (Apr 2026→Aug 2026) | -79.5% (Oct 2021→Sep 2026) |
AHCO earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 4, 2026 | Quarter ended Jun 30, 2026 | −$0.07 | $0.17 | Miss −$0.24 | -40.0% |
| May 5, 2026 | Quarter ended Mar 31, 2026 | −$0.05 | $0.01 | Miss −$0.06 | -12.4% |
| Feb 24, 2026 | Quarter ended Dec 31, 2025 | $0.27 | $0.34 | Miss −20.6% | -9.3% |
| Nov 4, 2025 | Quarter ended Sep 30, 2025 | $0.23 | $0.24 | Miss −4.2% | +13.8% |
| Aug 5, 2025 | — | — | — | — | +8.1% |
| May 6, 2025 | — | — | — | — | -5.3% |
| Feb 25, 2025 | — | — | — | — | +29.8% |
| Nov 5, 2024 | — | — | — | — | +0.3% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
AHCO recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 13, 2026 | Schedule 13G/A | REINHART PARTNERS, LLC.: 0.0% of shares, passive 5%+ holder (amended) |
| Oct 8, 2026 | Schedule 13G/A | Dimensional Fund Advisors LP: 4.7% of shares, passive 5%+ holder (amended) |
| Sep 8, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “Chief Financial Officer Appointment AdaptHealth Corp. (the "Company") announced today that Harriss Currie, age 64, has been appointed to serve as the Chief Financial Officer of the Company, effective as of September 9, 2026 (the "Start Date"). Mr. Currie served as Chief Financial Officer at Health Track RX, a developer of an infectious disease diagnostics platform, from December 2025 to May 2026. Previously, he served as President of the Regenerative Medicine Division of 3D Systems, a developer of high-resolution…” |
| Aug 4, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 4, 2026 | 8-K | Quarterly results |
| Jul 20, 2026 | 8-K | Entered a material agreement “Asset Purchase Agreement On July 19, 2026, AdaptHealth Corp., a Delaware corporation (the "Company"), entered into an asset purchase agreement (the "Purchase Agreement") by and between the Company and RGH Enterprises, LLC, an Ohio limited liability company and a wholly owned subsidiary of Cardinal Health, Inc. (the "Purchaser"). Under the Purchase Agreement, the Company has agreed to sell, and the Purchaser has agreed to purchase, substantially all of the assets related to the Company's business of providing…” |
| Jul 7, 2026 | 8-K | Regulation FD disclosure |
| Jul 2, 2026 | 8-K | Material cybersecurity incident “AdaptHealth Corp. (the "Company") is investigating a security incident whereby a threat actor gained unauthorized access to Company systems and exfiltrated certain data therefrom. Upon learning of the incident, the Company promptly activated its incident response procedures, launched the investigation with the support of external advisors and cybersecurity experts to assess and contain the threat and notified law enforcement. While the investigation is ongoing, the Company has been able to confirm certain facts…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
AHCO revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Sleep Health | $386.5M | 52.2% | +15.5% |
| Respiratory Health | $194.4M | 26.3% | +14.1% |
| Wellness at Home | $159.4M | 21.5% | +4.9% |
| Total revenue | $740.3M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
AHCO suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Cardinal Health (CAH) | “AdaptHealth competes with other large national providers, including Accendra Health, Lincare Holdings Inc., Rotech Healthcare, Inc., Cardinal Health, Inc. and Quipt Home Medical Corp; regional providers, including DASCO Home Medical Equipment, Binson's Medical Equipment, Inc., Norco, Inc., Protech Home Medical Corp., and Viemed Healthcare, Inc.; and product-specific providers, including Breg, Inc., Inogen, Inc., A…” |
| Competitor | CVS Health (CVS) | “In addition, AdaptHealth competes with non-HME providers, including CVS and Amazon.” |
| Competitor | Amazon (AMZN) | “In addition, AdaptHealth competes with non-HME providers, including CVS and Amazon.” |
| Competitor | UnitedHealth (UNH) | “In addition, pharmacy benefit managers, including CVS Health Corporation and the Optum business of UnitedHealth Group Incorporated, have entered the HME market and compete with AdaptHealth.” |
Quoted from the company's 10-K filed Feb 24, 2026.
AHCO customer concentration
In the period ended Dec 31, 2025, a single direct customer accounted for 26% of revenue, per the company's 10-K filed Feb 24, 2026. The company does not name it.
AHCO company outlook (results filed Aug 4, 2026)
- “The revised guidance also includes a $55 million impact related to our West Coast capitated contract; a $30 million impact from a manufacturer price increase; and a $15 million impact from other portfolio actions.”
Quoted word-for-word from the SEC 8-K results press release.
AHCO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.06 | $0.32 | −$0.38 | $725.9M | 5 |
| Next quarter (ends Dec 2026) | $-0.06 | $0.45 | −$0.51 | $731.1M | 5 |
| Current fiscal year (ends Dec 2026) | $-0.45 | $0.84 | −$1.29 | $2.88B | 5 |
| Next fiscal year (ends Dec 2027) | $-0.13 | $1.17 | −$1.30 | $2.99B | 5 |
AHCO options: expected move
Options price a move of about ±23.4% (±$1.40) by Dec 18, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±14.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Dec 18, 2026 | 51 | 67.4% | ±23.4% |
| Jan 15, 2027 | 79 | 77.4% | ±32.1% |
| Mar 19, 2027 | 142 | 51.2% | ±28.4% |
30-day implied volatility 76.4% vs 33.8% realized over the last 30 trading days. Put/call ratio (volume) 0.5. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 06:17 UTC)
| Price | USD 6.03 |
|---|---|
| Change | ▲ 3.08% (up) |
| Previous Close | USD 6.03 |
| Open | USD 6.03 |
| Day Range | USD 5.82 – 6.08 |
| 52-Week Range | USD 5.21 – 13.43 |
| Volume | 1,558,583 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (AHCO)
Nexqual's technical model rates AHCO "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 06:17 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.96 (neutral) |
| vs SMA50 | Above (USD 5.87) |
| MACD | -0 (negative) |
Earnings (AHCO)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.06 |
| Revenue Estimate | $725.87M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.07 vs est 0.17 ▼ miss |
| 2026-03-31 | USD -0.05 vs est 0.01 ▼ miss |
| 2025-12-31 | USD 0.27 vs est 0.34 ▼ miss |
| 2025-09-30 | USD 0.23 vs est 0.24 ▼ miss |
Source: Nexqual, October 29, 2026 at 06:17 UTC.
Financials & Fundamentals (AHCO)
| Total Revenue | $3.36B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +12.70% |
| Gross Margin | +19.17% |
| Operating Margin | +0.84% |
| Profit Margin | -6.79% |
| ROE | -15.22% |
| Debt / Equity | 1.49 |
| Current Ratio | 1.12 |
| Total Cash | $43.29M |
| Total Debt | $2.07B |
Source: Nexqual, October 29, 2026 at 06:17 UTC.
Ownership (AHCO)
| Insider Ownership | +8.28% |
|---|---|
| Institutional Ownership | +100.24% |
| Shares Outstanding | 133.41M |
| Float | 85.77M |
| Short % of Float | +10.21% |
Source: Nexqual, October 29, 2026 at 06:17 UTC.
Leadership (AHCO)
AdaptHealth Corp. is led by Suzanne M. Foster M.P.H., CEO & Director, per Nexqual as of October 29, 2026 at 06:17 UTC.
| CEO & Director | Suzanne M. Foster M.P.H. |
|---|---|
| CTO & Chief Innovation Officer | Albert A. Prast |
| Chief Financial Officer | Harriss T. Currie |
Major Backers & Investors (AHCO)
Notable institutional backers of AdaptHealth Corp. include OEP Capital Advisors, LP, Deerfield Management Company, L.P, Fidelity, according to Nexqual as of October 29, 2026 at 06:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| OEP Capital Advisors, LP | 11.96% |
| Deerfield Management Company, L.P | 8.42% |
| Fidelity | 6.78% |
| Skyknight Capital, L.p. | 6.29% |
| FMR, LLC | 5.78% |
| Principal Financial Group, Inc. | 2.42% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.78% |
| Vanguard Group | 8.26% |
| Dimensional Fund Advisors | 5.63% |
| State Street | 3.4% |
Source: Nexqual, October 29, 2026 at 06:17 UTC.
From AdaptHealth Corp.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services to revise regulations governing state-directed payment arrangements ("SDPs") to cap total payment rates paid by Medicaid managed care organizations for specified services, including hospital services, by tying caps to Medicare payment rates instead of average commercial rates and imposing lower caps in Expansion States.
Legal & Regulatory Risks (Item 1A, quoted)
- AdaptHealth's revenue could be impacted by federal and state changes to reimbursement and other Medicaid and Medicare policies.
- AdaptHealth's operations are subject to various state and federal fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal Stark Law and the federal False Claims Act. These laws may impact, among other things, AdaptHealth's sales, marketing and education programs.
- Failure by AdaptHealth to successfully design, modify and implement technology-based and other process changes to maximize productivity and ensure compliance could ultimately have a significant negative impact on AdaptHealth's financial condition, reputation and results of operations.
- Failure by AdaptHealth to maintain required licenses and accreditation could impact its operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OPCH | Option Care Health, Inc. | USD 31.29 | ▼ 0% |
| AXNX | Axonex AI Group Limited | USD 0.94 | ▲ 17.5% |
| ADUS | Addus HomeCare Corporation | USD 122.18 | ▲ 0.78% |
| RPAY | Repay Holdings Corporation | USD 4.42 | ▲ 3.03% |
| SIBN | SI-BONE, Inc. | USD 21.83 | ▲ 1.82% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:17 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt